Gene: LNX1

84708
LNX|MPDZ|PDZRN2
ligand of numb-protein X 1
protein-coding
4q12
Ensembl:ENSG00000072201 MIM:609732 Vega:OTTHUMG00000102099 UniprotKB:Q8TBB1
NC_000004.12
PubMed
0   ANCO-SNPs
CD|AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.577e-1 (AD)  2.695e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TMEM132D0.975
FRMPD40.973
KCNQ50.969
NMNAT20.969
KIAA1549L0.969
FAXC0.968
C11orf870.968
LMTK20.968
SLITRK50.968
PCSK20.968

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
HEY2-0.627
MYL3-0.624
YES1-0.597
RAB13-0.585
COPZ2-0.583
RNF135-0.579
REST-0.565
CHST14-0.557
RAI14-0.557
CSAG1-0.557

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in increased expression of LNX1 mRNA"20453058
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA"27188386
C016601afimoxifeneafimoxifene inhibits the reaction [Estrogens results in decreased expression of LNX1 mRNA]21233418
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of LNX1 mRNA27153756
D016604Aflatoxin B1Aflatoxin B1 results in increased methylation of LNX1 gene27153756
D001151ArsenicArsenic affects the methylation of LNX1 gene25304211
C015001arsenitearsenite results in increased methylation of LNX1 promoter23974009
C072553benzyloxycarbonylleucyl-leucyl-leucine aldehydebenzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of LNX1 mRNA20061341
D004958EstradiolEstradiol results in decreased expression of LNX1 mRNA23019147
C006780bisphenol A[bisphenol A co-treated with Testosterone] results in increased expression of LNX1 mRNA26496021
C006780bisphenol Abisphenol A results in decreased expression of LNX1 mRNA25181051
D019256Cadmium ChlorideCadmium Chloride results in increased expression of LNX1 mRNA20061341
D019256Cadmium ChlorideCadmium Chloride results in increased methylation of LNX1 promoter22457795
D020245p-Chloromercuribenzoic Acid"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA"27188386
D020245p-Chloromercuribenzoic Acidp-Chloromercuribenzoic Acid results in increased expression of LNX1 mRNA26272509
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of LNX1 mRNA20938992
C118739entinostatentinostat results in increased expression of LNX1 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA"27188386
D004967Estrogensafimoxifene inhibits the reaction [Estrogens results in decreased expression of LNX1 mRNA]21233418
D004967EstrogensEstrogens results in decreased expression of LNX1 mRNA21233418
D011345FenofibrateFenofibrate results in decreased expression of LNX1 mRNA21318169
D011345FenofibratePPARA protein affects the reaction [Fenofibrate results in decreased expression of LNX1 mRNA]21318169
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of LNX1 mRNA20938992
D004397FonofosFonofos results in increased methylation of LNX1 promoter22847954
D005839GentamicinsGentamicins results in decreased expression of LNX1 mRNA22061828
D007854LeadLead affects the expression of LNX1 mRNA28903495
C008261lead acetate[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of LNX1 mRNA22839698
C042720mercuric bromidemercuric bromide results in increased expression of LNX1 mRNA26272509
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA"27188386
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of LNX1 mRNA20938992
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of LNX1 mRNA20061341
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of LNX1 mRNA26011545
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of LNX1 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of LNX1 mRNA"25554681
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA"27188386
C496932panobinostatpanobinostat results in increased expression of LNX1 mRNA26272509
D010278ParathionParathion results in increased methylation of LNX1 promoter22847954
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of LNX1 mRNA26272509
C006253pirinixic acidpirinixic acid affects the expression of LNX1 mRNA17950772
C006253pirinixic acidpirinixic acid results in decreased expression of LNX1 mRNA21318169
C006253pirinixic acidpirinixic acid results in increased expression of LNX1 mRNA20813756
C006253pirinixic acidPPARA protein affects the reaction [pirinixic acid results in decreased expression of LNX1 mRNA]21318169
D011374ProgesteroneProgesterone results in increased expression of LNX1 mRNA19690047
C017947sodium arsenitesodium arsenite results in decreased expression of LNX1 mRNA28595984
D012999SomanSoman results in decreased expression of LNX1 mRNA19281266
D053260SootSoot results in decreased expression of LNX1 mRNA26551751
C012568terbufosterbufos results in increased methylation of LNX1 promoter22847954
D013739Testosterone[bisphenol A co-treated with Testosterone] results in increased expression of LNX1 mRNA26496021
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of LNX1 mRNA24935251|2627250
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA"27188386
D014635Valproic AcidValproic Acid results in increased expression of LNX1 mRNA23179753|2438349
D014635Valproic AcidValproic Acid affects the expression of LNX1 mRNA17292431
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of LNX1 gene25560391
C029297vinylidene chloridevinylidene chloride results in decreased expression of LNX1 mRNA26682919
C017803zinc protoporphyrin[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of LNX1 mRNA22839698

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004842ubiquitin-protein transferase activity-IEA-  
GO:0005515protein binding-IPI16002321  16189514  16713569  17936276  20864041  21516116  
25416956  25910212  27107012  27107014  
GO:0030165PDZ domain binding-IEA-  
GO:0046872metal ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006511ubiquitin-dependent protein catabolic process-IEA-  
GO:0016567protein ubiquitination-IEA-  
GO:0051260protein homooligomerization-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005737cytoplasm-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1280218Adaptive Immune SystemTAS
R-HSA-168256Immune SystemTAS
R-HSA-983168Antigen processing: Ubiquitination & Proteasome degradationTAS
R-HSA-983169Class I MHC mediated antigen processing & presentationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal